Skip to content

Clinical trials

Completed Leukemia, Megakaryoblastic, Acute trials in the United States

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Leukemia, Megakaryoblastic, Acute Status: Completed Country / region: United States Clear all

97 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20006
20012
20025
20032
200412
200510
20067
20075
20087
20093
20104
20114
20121
20136
20142

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed97

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
National Cancer Institute (NCI)33
Case Comprehensive Cancer Center10
Fred Hutchinson Cancer Center6
SWOG Cancer Research Network5
Roswell Park Cancer Institute4
Eastern Cooperative Oncology Group3
Memorial Sloan Kettering Cancer Center3
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3
Alliance for Clinical Trials in Oncology2
Children's Oncology Group2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Leukemia, Megakaryoblastic, Acute97
Leukemia, Erythroblastic, Acute95
Leukemia, Myeloid, Acute95
Leukemia, Monocytic, Acute89
Leukemia, Myelomonocytic, Acute88
Congenital Abnormalities65
Leukemia46
Leukemia, Basophilic, Acute31
Leukemia, Eosinophilic, Acute31
Precursor Cell Lymphoblastic Leukemia-Lymphoma30

Trials

Showing 1 to 25 of 97. Each trial links to its page on Pharma Observatory.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.